Assessment of the efficiency of the local application of hemostatic drug Geprocel in the treatment of patients with deep burns

The work is based on the analysis of the treatment results of 35 patients with burn trauma (10 women and 25 men) aged 15 to 55 years who were treated in the burn department of Republican Scientific Centre of Urgent Medical Aid (RSCUMA) between 2017 and 2018. In this study, we report on the use of the hemostatic preparation Geprocel with an autodermoplasty on a wound after necroectomy with subsequent autodermoplasty in all cases contributed to the complete healing of donor sites for 7 days, and the complete engraftment of the skin autotransplant with full recovery of the defect by 12 days after surgery. This preliminary data suggests the potential role of Geprocel in the clinical management of burn treatment.The work is based on the analysis of the treatment results of 35 patients with burn trauma (10 women and 25 men) aged 15 to 55 years who were treated in the burn department of Republican Scientific Centre of Urgent Medical Aid (RSCUMA) between 2017 and 2018. In this study, we report on the use of the hemostatic preparation Geprocel with an autodermoplasty on a wound after necroectomy with subsequent autodermoplasty in all cases contributed to the complete healing of donor sites for 7 days, and the complete engraftment of the skin autotransplant with full recovery of the defect by 12 days after surgery. This preliminary data suggests the potential role of Geprocel in the clinical management of burn treatment

Synthesis, Characterization, and In Vivo

[Image: see text] The use of nebulizable, nanoparticle-based antimicrobial delivery systems can improve efficacy and reduce toxicity for treatment of multi-drug-resistant bacteria in the chronically infected lungs of cystic fibrosis patients. Nanoparticle vehicles are particularly useful for applying broad-spectrum silver-based antimicrobials, for instance, to improve the residence time of small-molecule silver carbene complexes (SCCs) within the lung. Therefore, we have synthesized multifunctional, shell cross-linked knedel-like polymeric nanoparticles (SCK NPs) and capitalized on the ability to independently load the shell and core with silver-based antimicrobial agents. We formulated three silver-loaded variants of SCK NPs: shell-loaded with silver cations, core-loaded with SCC10, and combined loading of shell silver cations and core SCC10. All three formulations provided a sustained delivery of silver over the course of at least 2–4 days. The two SCK NP formulations with SCC10 loaded in the core each exhibited excellent antimicrobial activity and efficacy in vivo in a mouse model of Pseudomonas aeruginosa pneumonia. SCK NPs with shell silver cation-load only, while efficacious in vitro, failed to demonstrate efficacy in vivo. However, a single dose of core SCC10-loaded SCK NPs (0.74 ± 0.16 mg Ag) provided a 28% survival advantage over sham treatment, and administration of two doses (0.88 mg Ag) improved survival to 60%. In contrast, a total of 14.5 mg of Ag(+) delivered over 5 doses at 12 h intervals was necessary to achieve a 60% survival advantage with a free-drug (SCC1) formulation. Thus, SCK NPs show promise for clinical impact by greatly reducing antimicrobial dosage and dosing frequency, which could minimize toxicity and improve patient adherence